TMDX

STRUCTURAL EDGE

• Only FDA-cleared normothermic perfusion system across all three solid-organ modalities (heart, lung, liver); no direct platform competitor has achieved that breadth.

• National OCS Program converts a device sale into a recurring per-case service fee (~$40K-$60K/case) - transforming episodic capital equipment revenue into a volume-driven annuity tied to US transplant throughput.

• Transplant volume is supply-constrained, not demand-constrained; OCS expands the usable donor pool by resuscitating marginal organs that would be discarded under cold storage, creating net-new addressable volume rather than share-taking.

• Proprietary flight network and 24/7 perfusionist staffing create a logistics moat that is operationally difficult to replicate quickly.

• International expansion (OCS Heart/Lung EU) provides a second growth vector uncorrelated to US reimbursement cycles.

BULL CASE

• TAM expansion: ~40,000 annual US solid-organ transplants; penetration still sub-30% in addressable categories.

• NOP gross margins structurally improve as flight utilization rises on a largely fixed cost base.

• CMS reimbursement codes for machine perfusion, once formalized, de-risk hospital budget friction.

• Pipeline: OCS Kidney in development - kidneys are the highest-volume transplant category (~25,000/yr US).

• First-mover regulatory moat: FDA 510(k)/PMA pathway for a competing system takes 5-7 years minimum.

BEAR CASE

• Revenue concentration: NOP economics are lumpy and dependent on case scheduling; a logistics disruption (FAA, weather, staffing) can materially shift quarterly results.